PLCG1 and breast carcinoma: Although the mechanisms involved remain to be defined, the activation of PLCγ1 as assessed by immunohistochemistry is a strong prognostic factor that can discriminate between high-risk and low-risk patients with hormone-receptor-positive early breast cancers.